文献速递核素与放射性配体治疗

钇-90玻璃微球放射栓塞治疗神经内分泌肿瘤肝转移的剂量-反应关系

Dose-response relationship after yttrium-90-radioembolization with glass microspheres in patients with neuroendocrine tumor liver metastases.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-12-07

本研究纳入26例神经内分泌肿瘤肝转移患者(31次操作、128个肿瘤),评估钇-90玻璃微球放射栓塞后肿瘤吸收剂量与疗效的关系。在校正肿瘤体积混杂后,吸收剂量对疗效有显著影响(p=0.0465),未发现显著的剂量-毒性关系。作者提出计划肿瘤吸收剂量绝对最低为150 Gy。

要点

  • 缓解肿瘤的吸收剂量几何均值为170 Gy,稳定疾病为101 Gy,进展疾病为67 Gy。
  • 校正肿瘤体积混杂后,吸收剂量对疗效有显著影响(p=0.0465)。
  • 未发现显著的剂量-毒性关系。

核心结论

  • 在钇-90放射栓塞治疗的神经内分泌肿瘤肝转移患者中,发现明确的剂量-反应关系。
  • 作者提出以计划肿瘤吸收剂量绝对最低150 Gy进行钇-90放射栓塞。

研究设计与样本

  • 纳入本中心所有接受钇-90玻璃微球放射栓塞、且治疗前后增强CT和注射后PET/CT均 available 的患者。
  • 共26例患者(31次操作)的128个肿瘤纳入疗效分析。
  • 勾画最多5个肝脏肿瘤及健康肝组织,用注射后PET/CT定量吸收剂量。
  • 按RECIST 1.1在患者水平和肿瘤水平评估疗效。
  • 肿瘤水平采用线性混合模型研究吸收剂量与疗效的关系,患者水平采用逻辑回归分析剂量-反应及肝脏剂量-毒性关系。

主要发现

  • 校正肿瘤体积混杂后,吸收剂量对疗效有显著影响(p=0.0465)。
  • 缓解肿瘤的吸收剂量几何均值为170 Gy,稳定疾病为101 Gy,进展疾病为67 Gy。
  • 未发现显著的剂量-毒性关系。

关键数值与推荐

  • 缓解肿瘤吸收剂量几何均值170 Gy,稳定疾病101 Gy,进展疾病67 Gy。
  • 校正肿瘤体积后吸收剂量对疗效影响显著(p=0.0465)。
  • 作者提出计划肿瘤吸收剂量绝对最低150 Gy。

临床怎么用

  • 作者提出以计划肿瘤吸收剂量绝对最低150 Gy进行钇-90放射栓塞。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In radioembolization, response is achieved through the irradiation and damaging of tumor DNA. For hepatic metastases of neuroendocrine tumors, a dose-response relationship has not been established yet. This study assesses whether increasing tumor-absorbed doses lead to increased response rates. METHODS: We included all patients who underwent yttrium-90 (90Y) glass microspheres radioembolization in our center if both pre- and post-treatment contrast-enhanced CT and post-injection PET/CT were available. Up to five hepatic tumors and the healthy hepatic tissue were delineated, and absorbed dose was quantified using post-injection PET/CT. Response was measured according to RECIST 1.1 on patient and tumor level. Linear mixed models were used to study the relationship between absorbed dose and response on tumor level. Logistic regression analysis was used on patient level to study dose-response and hepatic dose-toxicity relationships. RESULTS: A total of 128 tumors in 26 patients (31 procedures) were included in the response analysis. While correcting for confounding by tumor volume, a significant effect of response on dose was found (p = 0.0465). Geometric mean of absorbed dose for responding tumors was 170 Gy, for stable disease 101 Gy, and for progressive disease 67 Gy. No significant dose-toxicity relationship could be identified. CONCLUSION: In patients with neuroendocrine tumor liver metastases, treated with 90Y-radioembolization, a clear dose-response relationship was found. We propose to perform 90Y-radioembolization with an absolute minimum planned tumor-absorbed dose of 150 Gy.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Ebbers SC, van Roekel C, Braat MNGJA, et al. Dose-response relationship after yttrium-90-radioembolization with glass microspheres in patients with neuroendocrine tumor liver metastases. Eur J Nucl Med Mol Imaging. 2021. PMID: 34873638. doi:10.1007/s00259-021-05642-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。